PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Purchased by Alliancebernstein L.P.

Alliancebernstein L.P. lifted its holdings in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 14.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,752,478 shares of the company’s stock after acquiring an additional 218,148 shares during the quarter. Alliancebernstein L.P. owned about 3.36% of PROCEPT BioRobotics worth $141,110,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of PRCT. Charles Schwab Investment Management Inc. raised its holdings in shares of PROCEPT BioRobotics by 13.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 402,565 shares of the company’s stock valued at $32,254,000 after buying an additional 46,665 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of PROCEPT BioRobotics by 34.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,316 shares of the company’s stock valued at $1,067,000 after purchasing an additional 3,403 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of PROCEPT BioRobotics by 2.7% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 116,460 shares of the company’s stock worth $9,331,000 after purchasing an additional 3,083 shares in the last quarter. PEAK6 Investments LLC acquired a new position in shares of PROCEPT BioRobotics during the third quarter worth $353,000. Finally, Verition Fund Management LLC purchased a new position in shares of PROCEPT BioRobotics in the third quarter valued at $2,132,000. Institutional investors and hedge funds own 89.46% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Truist Financial reiterated a “buy” rating and issued a $90.00 price objective (down previously from $105.00) on shares of PROCEPT BioRobotics in a report on Wednesday, February 26th. Wells Fargo & Company reiterated an “overweight” rating and issued a $112.00 price target on shares of PROCEPT BioRobotics in a research note on Tuesday, December 3rd. Finally, Morgan Stanley lowered their price objective on PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, PROCEPT BioRobotics presently has a consensus rating of “Moderate Buy” and a consensus price target of $94.29.

PROCEPT BioRobotics Stock Down 2.0 %

NASDAQ:PRCT opened at $57.09 on Wednesday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. The company has a market capitalization of $3.13 billion, a price-to-earnings ratio of -29.28 and a beta of 1.05. PROCEPT BioRobotics Co. has a one year low of $45.56 and a one year high of $103.81. The stock has a 50-day simple moving average of $64.98 and a 200 day simple moving average of $77.66.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its earnings results on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The firm had revenue of $68.24 million during the quarter, compared to analyst estimates of $66.79 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. Sell-side analysts predict that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.

Insider Buying and Selling at PROCEPT BioRobotics

In other news, CFO Kevin Waters sold 733 shares of PROCEPT BioRobotics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $41,824.98. Following the completion of the transaction, the chief financial officer now directly owns 107,991 shares of the company’s stock, valued at approximately $6,161,966.46. The trade was a 0.67 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Reza Zadno sold 5,475 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $312,403.50. Following the sale, the chief executive officer now owns 173,070 shares in the company, valued at approximately $9,875,374.20. This trade represents a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,455 shares of company stock worth $368,322 over the last 90 days. Insiders own 17.40% of the company’s stock.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).